Children's Oncology Group's 2023 blueprint for research: Renal tumors

Author:

Geller James I.1ORCID,Hong Andrew L.2,Vallance Kelly L.3ORCID,Evageliou Nick4,Aldrink Jennifer H.5ORCID,Cost Nicholas G.6,Treece Amy L.7,Renfro Lindsay A.8,Mullen Elizabeth A.9,

Affiliation:

1. Division of Oncology, Cincinnati Children's Hospital Medical Center University of Cincinnati Cincinnati Ohio USA

2. Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta Emory University School of Medicine Atlanta Georgia USA

3. Hematology and Oncology Cook Children's Medical Center Fort Worth Texas USA

4. Division of Oncology Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

5. Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital The Ohio State University College of Medicine Columbus Ohio USA

6. Department of Surgery, Division of Urology and the Surgical Oncology Program at Children's Hospital Colorado University of Colorado School of Medicine Aurora Colorado USA

7. Department of Pathology and Laboratory Medicine Children's of Alabama Birmingham Alabama USA

8. Keck School of Medicine of USC Los Angeles California USA

9. Dana‐Farber/Boston Children's Blood Disorders and Cancer Center Boston Massachusetts USA

Abstract

AbstractEvery year, approximately 600 infants, children, and adolescents are diagnosed with renal cancer in the United States. In addition to Wilms tumor (WT), which accounts for about 80% of all pediatric renal cancers, clear cell sarcoma of the kidney, renal cell carcinoma, malignant rhabdoid tumor, as well as more rare cancers (other sarcomas, rare carcinomas, lymphoma) and benign tumors can originate within the kidney. WT itself can be divided into favorable histology (FHWT), with a 5‐year overall survival (OS) exceeding 90%, and anaplastic histology, with 4‐year OS of 73.7%. Outcomes of the other pediatric renal cancers include clear cell sarcoma (5‐year OS: 90%), malignant rhabdoid tumor (5‐year OS: 10% for stages 3 and 4), and renal cell carcinoma (4‐year OS: 84.8%). Recent clinical trials have identified novel biological prognostic markers for FHWT, and a series of Children's Oncology Group (COG) trials have demonstrated improving outcomes with therapy modification, and opportunities for further care refinement.

Funder

National Institutes of Health

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3